SHENZHEN, China--(BUSINESS WIRE)--Tongjitang Chinese Medicines Company (NYSE: TCM - News), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that Mr. Shaolan Wang resigned as the chief financial officer and a director of the Company on August 12, 2008 due to personal health reasons. The Company appointed Eric Chan, Tongjitang’s financial controller, as interim chief financial officer and is beginning a search for a new chief financial officer.
Xiaochun Wang, Tongjitang’s chief executive officer and chairman of the board of directors, stated, “I’d like to thank Mr. Shaolan Wang for his dedication and contribution to Tongjitang over the years since the inception of the company and wish him all the best in the future.”
About Tongjitang Chinese Medicines Company
Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, and Tongjitang Planting, is a vertically integrated and profitable specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang’s principal executive offices are located in Shenzhen, China.
Tongjitang’s flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 18 other modernized traditional Chinese medicine products and 38 western medicines. Please visit www.tongjitang.com for more information.
Contact:
Integrated Corporate Relations, Inc.
Ashley M. Ammon or Christine Duan
203-682-8200 (Investor Relations)
Source: Tongjitang Chinese Medicines Company